Breez

Throughout the period from August to November 2023, Breez demonstrated a consistent performance in the Capsules category in California, maintaining the 2nd rank each month. This consistency indicates a strong demand for their Capsules product line. However, the brand's sales in this category showed a slight downward trend over the four months. In the Edibles category, Breez experienced fluctuations in their ranking, ranging from 25th to 30th place. The brand's sales in this category also saw a decline, which may suggest a need for strategic adjustments to regain market share.

In the Tincture & Sublingual category, Breez's ranking in California slightly worsened from 10th place in August to 12th in November. This downward shift in ranking was accompanied by a decrease in sales. In the Topical category, Breez's ranking fluctuated between 23rd and 26th place. Despite these changes in ranking, the brand's sales in this category remained relatively stable. It's worth noting that Breez did not appear in the top 20 brands in any of the categories in November, which indicates room for improvement in their market performance.

In the Capsules category within the California market, Breez has maintained a steady rank at second place from August to November 2023, indicating a strong and consistent performance. However, it's worth noting that Breez's closest competitor, Level, has consistently outperformed Breez, holding the top rank in the same period. This suggests that while Breez is a strong player, there is still room for growth and improvement. On the other hand, Breez has consistently ranked higher than both ABX / AbsoluteXtracts and Kikoko, which have fluctuated between the third and fourth ranks. This indicates that Breez has a competitive edge over these brands, despite the dynamic nature of the market. The long-term trend suggests a slight decrease in sales for Breez, which could be an area of concern and warrants further investigation.

In November 2023, the top-performing products from Breez were primarily from the Capsules category. The Indica Extra Strength Tablet 50-Pack (1000mg) retained its position as the top-selling product, with sales reaching 11,260 units. Following closely in second place was the Sativa Extra Strength Tablet 50-Pack (1000mg), which saw a slight decrease in sales compared to previous months, selling 10,086 units. The Hybrid Extra-Strength Tablet 50-Pack (1000mg) consistently held the third position. The only product from the Edible category, Sativa Royal Mint 20-Pack (100mg), managed to maintain its fourth position, while the CBD/THC 1:1 Relief Extra Strength Tablets 50-Pack (500mg CBD, 500mg THC) rounded out the top five.